# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
On January 17, 2023, the parties received written notice from CFIUS that it had determined that there were no unresolved nation...
As previously disclosed, on October 18, 2022, AVEO Pharmaceuticals, Inc., a Delaware corporation (“AVEO”), entered into an Agre...
AVEO Oncology ("AVEO") (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to deliv...
-SEC Filing
https://www.scribd.com/document/609450380/Aveo-Patent
Upgrades
Within the last quarter, AVEO Pharmaceuticals (NASDAQ:AVEO) has observed the following analyst ratings:
Stifel analyst Stephen Willey downgrades AVEO Pharmaceuticals (NASDAQ:AVEO) from Buy to Hold and announces $15 price target.
AVEO Pharmaceuticals (NASDAQ:AVEO) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of ...